Due to a high load of modelling projects, the rate of submission via the website has been reduced.
For a much higher submission rate, please use the Modelling API.

A0A2K6P9I2 (A0A2K6P9I2_RHIRO) Rhinopithecus roxellana (Golden snub-nosed monkey) (Pygathrix roxellana)

Cyclin-dependent kinase 2 UniProtKBInterProInteractive Modelling

298 aa; Sequence (Fasta) ; 17 identical sequences

Available Structures

459 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Thr 160 phosphorylated CDK2 H84S, Q85M, K89D - human cyclin A3 complex with ATP Heteromer
P20248; P24941;
1-298
ATP;MG;SGM;
Assess
CDK2/CyclinA in complex with AZD5438 Heteromer
P24941; P30274;
1-298
FB8;
Assess
Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor meriolin 3 Heteromer
P24941; P30274;
1-298
MFR;MG;SGM;
Assess
Thr 160 phosphorylated CDK2 K89D, Q131E - human cyclin A3 complex with the inhibitor RO3306 Heteromer
P20248; P24941;
1-298
1RO;DMS;SGM;
Assess
Structure of CDK2/cyclin A in complex with CAN508 Heteromer
P24941; P30274;
1-298
F18;
Assess
CDK2/Cyclin A covalent complex with 6-(cyclohexylmethoxy)-N-(4-(vinylsulfonyl)phenyl)-9H-purin-2-am… Heteromer
P20248; P24941;
1-298
55S;
Assess
Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor Heteromer
P24941; P30274;
1-298
T6Q;SGM;SO4;
Assess
CDk2/cyclinA in complex with DRB Heteromer
P24941; P30274;
1-298
RFZ;FMT;SGM;
Assess
Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor variolin B Heteromer
P24941; P30274;
1-298
VAR;MG;SGM;
Assess
Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. Heteromer
P20248; P24941;
1-298
2WC;MG;
Assess
Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor Heteromer
P20248; P24941;
1-298
T3C;SO4;SGM;
Assess
CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX Heteromer
P20248; P24941;
1-298
ATP;
Assess
Structure of CDK2/Cyclin A with PNU-292137 Heteromer
P20248; P24941;
1-298
SO4;292;
Assess
Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor meriolin 5 Heteromer
P24941; P30274;
1-298
MHR;MG;
Assess
Thr 160 phosphorylated CDK2 H84S, Q85M, Q131E - human cyclin A3 complex with the inhibitor RO3306 Heteromer
P20248; P24941;
1-298
1RO;MG;
Assess
Structure of phopsho-CDK2-cyclin A in complex with an ATP-competitive inhibitor Heteromer
P20248; P24941;
1-298
6ZK;SGM;MG;
Assess
STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 Heteromer
P20248; P24941;
1-298
529;SO4;
Assess
CDK-2-Cyclin complex with indazole inhibitor 9 bound at its active site Heteromer
P20248; P24941;
1-298
GOL;EZV;SO4;
Assess
STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125 Heteromer
P20248; P24941;
1-298
P48;
Assess
CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2 Heteromer
P24941; P89883;
1-298
CL;
Assess
Structure of Thr 160 phosphorylated CDK2/cyclin A in complex with the inhibitor NU6271 Heteromer
P24941; P30274;
1-298
NU5;
Assess
Optimisation of 6,6-Dimethyl Pyrrolo 3,4-c pyrazoles: Identification of PHA-793887, a Potent CDK In… Heteromer
P20248; P24941;
1-298
SO4;889;
Assess
Crystal structure of the Cyclin A-CDK2-ORC1 complex Heteromer
P20248; P24941; Q13415;
1-298
PO4;
Assess
PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A Heteromer
P20248; P24941;
1-298
MN;ATP;
Assess
Structure of CDK2-CYCLIN A with a Pyrazolo(4,3-h) quinazoline-3- carboxamide inhibitor Heteromer
P20248; P24941;
1-298
WXV;SO4;
Assess
STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 Heteromer
P20248; P24941;
1-298
SBC;SO4;
Assess
Crystal structure apo CDK2/cyclin A Heteromer
P20248; P24941;
1-298
Assess
CDK2/CyclinA in complex with CGP74514A Heteromer
P24941; P30274;
1-298
23D;
Assess
Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor CR8 Heteromer
P24941; P30274;
1-298
RC8;
Assess
Crystal Structure of the CDK2/Cyclin A complex with oxindole inhibitor Heteromer
P20248; P24941;
1-298
60K;DTT;
Assess
THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR Heteromer
P20248; P24941;
1-298
107;
Assess
STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1-METHYL-4,5-DIHYDRO- 1H-PYRAZOLO[4,3-H] QUINAZ… Heteromer
P20248; P24941;
1-298
P49;
Assess
Cdk2/CyclinA complexed with a imidazo triazin-2-amine Heteromer
P20248; P24941;
1-298
T2A;
Assess
CDK2/CyclinA complexed with a pyrazolopyridazine inhibitor Heteromer
P20248; P24941;
1-298
5BP;
Assess
Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. Heteromer
P20248; P24941;
1-298
G6T;
Assess
Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor roscovitine Heteromer
P24941; P30274;
1-297
RRC;SGM;
Assess
CDK2-CyclinE1 in complex with allosteric inhibitor I-198. Heteromer
P24864; P24941;
1-297
A1AC4;
Assess
CDK2-CyclinE1 in complex with allosteric inhibitor I-125A. Heteromer
P24864; P24941;
1-297
A1AC5;
Assess
Thr 160 phosphorylated CDK2 Q131E - human cyclin A3 complex with the inhibitor RO3306 Heteromer
P20248; P24941;
1-297
1RO;SGM;
Assess
Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-pu… Heteromer
P20248; P24941;
1-297
N76;SGM;MG;
Assess
Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor Heteromer
P20248; P24941;
1-297
T3E;SGM;
Assess
Structure of CDK2 in complex with FP19711, a Helicon Polypeptide Heteromer
P24941;
2-298
NH2;WHL;
Assess
Thr 160 phosphorylated CDK2 Q131E - human cyclin A3 complex with ATP Heteromer
P20248; P24941;
1-297
MG;ATP;SGM;
Assess
Thr 160 phosphorylated CDK2 H84S, Q85M, Q131E - human cyclin A3 complex with ATP Heteromer
P20248; P24941;
1-297
ATP;MG;
Assess
Thr 160 phosphorylated CDK2 WT - human cyclin A3 complex with ATP Heteromer
P20248; P24941;
1-297
ATP;MG;SGM;
Assess
The structural basis of CDK2 activation by cyclin E Heteromer
P24864; P24941;
1-297
Assess
Crystal structure of CDK2/cyclin E in complex with PF-06873600 Heteromer
P24864; P24941;
1-297
WG1;
Assess
Thr 160 phosphorylated CDK2 WT - human cyclin A3 complex with the inhibitor NU6102 Heteromer
P20248; P24941;
1-297
4SP;
Assess
CDK2/CyclinA in complex with an 11-residue recruitment peptide from p27 Heteromer
P20248; P24941; P46527;
1-297
Assess
CDK2/CyclinA in complex with an 11-residue recruitment peptide from p53 Heteromer
P04637; P20248; P24941;
1-297
Assess
Mechanism of CDK inhibition by active site phosphorylation: CDK2 Y15p T160p in complex with cyclin … Heteromer
P20248; P24941;
1-297
ATP;
Assess
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V-H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGU… Heteromer
P20248; P24941;
1-297
4SP;SGM;
Assess
Thr 160 phosphorylated CDK2 H84S, Q85M, K89D - human cyclin A3 complex with the inhibitor RO3306 Heteromer
P20248; P24941;
1-297
1RO;SGM;MG;
Assess
Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor Heteromer
P20248; P24941;
1-297
C94;
Assess
Complex structure of CDK2/Cyclin E1 and a potent, selective macrocyclic inhibitor Heteromer
P24864; P24941;
1-297
WZU;
Assess
Thr 160 phosphorylated CDK2 H84S, Q85M, K89D - human cyclin A3 complex with the inhibitor NU6102 Heteromer
P20248; P24941;
1-297
4SP;SGM;
Assess
Thr 160 phosphorylated CDK2 WT - human cyclin A3 complex with the inhibitor RO3306 Heteromer
P20248; P24941;
1-297
1RO;
Assess
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-N… Heteromer
P20248; P24941;
1-297
ST8;SGM;
Assess
STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 Heteromer
P20248; P24941;
1-297
SO4;514;
Assess
Structure of Thr 160 phosphorylated CDK2/cyclin A in complex with the inhibitor N-&-N1 Heteromer
P24941; P30274;
1-297
NNN;SGM;
Assess
Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design Heteromer
P20248; P24941;
1-297
X1N;
Assess
The X-ray co-crystal structure of human CDK2/CyclinE and Dinaciclib. Heteromer
P24864; P24941;
1-297
1QK;GOL;
Assess
Cdk2/Cyclin A complexed with a thiophene carboxamide inhibitor Heteromer
P20248; P24941;
1-297
BLZ;
Assess
Complex structure of CDK2/Cyclin E1 and a potent, selective small molecule inhibitor Heteromer
P24864; P24941;
1-297
WZZ;
Assess
CDK2/CyclinA complexed with a pyrazolopyridazine inhibitor Heteromer
P20248; P24941;
1-297
PO5;
Assess
Crystal structure of SUN1-Speedy A-CDK2 Heteromer
O94901; P24941; Q5MJ70;
2-298
GOL;ZN;
Assess
The crystal structure of CDK2 cyclin A in complex with a substrate peptide derived from CDC modifie… Heteromer
P20248; P24941; Q99741;
1-296
ATP;SO4;GOL;
Assess
Structure of a pCDK2/CyclinA transition-state mimic Heteromer
P24941; P51943;
1-296
ADP;MG;MGF;CL;DTU;
Assess
CDK2/CyclinA in complex with SU9516 Heteromer
P24941; P30274;
1-296
SU9;
Assess
Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6086 Heteromer
P20248; P24941;
1-296
6CP;
Assess
Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6102 Heteromer
P20248; P24941;
1-296
4SP;
Assess
Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. Heteromer
P20248; P24941;
1-296
75X;MG;
Assess
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR Heteromer
P20248; P24941;
1-296
4SP;SGM;MG;
Assess
Structure of pCDK2/CyclinA bound to ADP and 2 Magnesium ions Heteromer
P24941; P51943;
1-296
ADP;MG;GOL;CL;
Assess
REPLACE: A strategy for Iterative Design of Cyclin Binding Groove Inhibitors Heteromer
P20248; P24941;
1-296
MTZ;GVC;
Assess
Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-pu… Heteromer
P20248; P24941;
1-296
N20;SGM;MG;
Assess
Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU2058 Heteromer
P20248; P24941;
1-296
CMG;
Assess
Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design Heteromer
P20248; P24941;
1-296
CK2;
Assess
Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design Heteromer
P20248; P24941;
1-296
CK8;
Assess
Structure of PCDK2/CYCLINA bound to ADP and 1 MAGNESIUM ION Heteromer
P24941; P51943;
1-296
ADP;MG;GOL;
Assess
Structure of a pCDK2/CyclinA transition-state mimic Heteromer
P24941; P51943;
1-296
ADP;MG;MGF;CL; 10×GOL;
Assess
PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX Heteromer
P20248; P24941;
1-296
ATP;MG;
Assess
The structure of phospho-CDK2/cyclin A in complex with the inhibitor 4,5,6,7-tetrabromobenzotriazol… Heteromer
P20248; P24941;
1-296
TBS;
Assess
THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A Heteromer
P20248; P24941;
1-296
UCN;
Assess
Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design Heteromer
P20248; P24941;
1-296
CK7;
Assess
Cyclin A binding groove inhibitor H-Arg-Arg-Leu-Ile-Phe-NH2 Heteromer
P20248; P24941;
1-296
Assess
Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor Heteromer
P20248; P24941;
1-296
C95;
Assess
Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-pu… Heteromer
P20248; P24941;
1-296
N41;SGM;MG;
Assess
Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. Heteromer
P20248; P24941;
1-296
SQ9;
Assess
Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor Heteromer
P20248; P24941;
1-296
T7Z;SGM;
Assess
Thr 160 phosphorylated CDK2 - Human cyclin A3 complex with the inhibitor indirubin-5-sulphonate bou… Heteromer
P20248; P24941;
1-296
INR;
Assess
Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6094 Heteromer
P20248; P24941;
1-296
2A6;
Assess
Cyclin A binding groove inhibitor Ac-Arg-Arg-Leu-Asn-(m-Cl-Phe)-NH2 Heteromer
P20248; P24941;
1-296
Assess
CDK2/CyclinA in complex with Flavopiridol Heteromer
P24941; P30274;
1-296
F9Z;
Assess
Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design Heteromer
P20248; P24941;
1-296
Assess
Cyclin A binding groove inhibitor Ace-Arg-Lys-Leu-Phe-Gly Heteromer
P20248; P24941;
1-296
Assess
REPLACE: A strategy for Iterative Design of Cyclin Binding Groove Inhibitors Heteromer
P20248; P24941;
1-296
C35;
Assess
Cyclin A binding groove inhibitor H-Arg-Arg-Leu-Asn-(p-F-Phe)-NH2 Heteromer
P20248; P24941;
1-296
Assess
Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment sit… Heteromer
P20248; P24941;
1-296
MG;
Assess
Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor Heteromer
P20248; P24941;
1-296
DT5;
Assess
Crystal structure of phospho-CDK2 Cyclin A in complex with a peptide containing both the substrate … Heteromer
P20248; P24941; Q99741;
1-296
ATP;MG;
Assess
Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor Heteromer
P20248; P24941;
1-296
C75;
Assess
pCDK2/cyclin A in complex with MgADP, nitrate and peptide substrate Heteromer
P20248; P24941;
1-296
ATP;MG;NO3;GOL;
Assess
Crystal structure of human Cdk2-Spy1 complex Heteromer
P24941; Q5MJ70;
1-296
Assess
Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor Heteromer
P20248; P24941;
1-296
C85;
Assess
CDK2/CyclinA in complex with an 11-residue recruitment peptide from p107 Heteromer
P20248; P24941; P28749;
1-296
Assess
Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment sit… Heteromer
P20248; P24941;
1-296
Assess
Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. Heteromer
P20248; P24941;
1-296
4QE;
Assess
Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design Heteromer
P20248; P24941;
1-296
Assess
Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design Heteromer
P20248; P24941;
1-296
MTW;
Assess
Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design Heteromer
P20248; P24941;
1-296
CK4;
Assess
Cyclin A binding groove inhibitor H-Cit-Cit-Leu-Ile-(p-F-Phe)-NH2 Heteromer
P20248; P24941;
1-296
Assess
CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2 Heteromer
P24941; Q16667;
1-296
MG;ATP;
Assess
Crystal Structure Analysis of human CDK2 and CCNA2 complex Heteromer
P20248; P24941;
1-296
ZGY;
Assess
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR Heteromer
P20248; P24941;
1-295
QQ2;SGM;MG;
Assess
CDK2/Cyclin A in complex with compound 73 Heteromer
P20248; P24941;
1-295
72L;
Assess
Crystal structure of Cyclin-dependent kinase 2/cyclin A in complex with 3,5,7-Substituted pyrazolo[… Heteromer
P20248; P24941;
1-294
D5P;GOL;EDO;PEG;SGM;
Assess
CDK2/cyclin A2 in complex with an imidazo[1,2-c]pyrimidin-5-one inhibitor Heteromer
P20248; P24941;
1-294
R7B;EDO;NA;
Assess
Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor Heteromer
P20248; P24941;
1-294
T9N;SO4;
Assess
Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. Heteromer
P20248; P24941;
1-294
JYM;DTT;
Assess
Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor Heteromer
P24941; P30274;
1-294
TJF;
Assess
CDK2/cyclin A2 in complex with pyrazolo[4,3-d]pyrimidine inhibitor LGR6768 Heteromer
P20248; P24941;
1-294
P2V;GOL;EDO;
Assess
CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1 Heteromer
P24941; P61024;
1-294
Assess
Crystal structure of human Cdk2-Spy1 complex Heteromer
P24941; Q5MJ70;
3-296
Assess
CDK2/CyclinA in complex with a 9 residue recruitment peptide from E2F Heteromer
P20248; P24941; Q01094;
1-293
Assess
CDK2/Cyclin A in complex with an 11-residue recruitment peptide from retinoblastoma-associated prot… Heteromer
P06400; P20248; P24941;
1-293
Assess
CDK2/cyclin A2 in complex with 3H-pyrazolo[4,3-f]quinoline-based derivative HSD1368 Heteromer
P20248; P24941;
1-293
T1T;NO3;SO4;
Assess
CDK2/cyclin A2 in complex with pyrazolo[4,3-d]pyrimidine inhibitor LGR4455 Heteromer
P20248; P24941;
1-290
FCQ;EDO;CL;BR;PG4;SGM;PGE;
Assess
CDK2/cyclin A2 in complex with open-ring 5-nitrosopyrimidine inhibitor LC436 Heteromer
P20248; P24941;
1-290
K4W;NA;GOL;
Assess
Crystal structure of phospho-CDK2 in complex with Cyclin B Heteromer
P14635; P24941;
1-288
Assess
P27(KIP1)/CYCLIN A/CDK2 COMPLEX Heteromer
P20248; P24941; P46527;
13-298
SO4;
Assess
Ubiquitin ligation to F-box protein substrates by SCF-RBR E3-E3 super-assembly: CUL1-RBX1-SKP1-SKP2… Heteromer
P20248; P24941; P46527; P61024; P63208; Q13309; Q13616;
13-298
Assess
Ubiquitin ligation to F-box protein substrates by SCF-RBR E3-E3 super-assembly: NEDD8-CUL1-RBX1-SKP… Heteromer
P0CG48; P20248; P24941; P46527; P61024; P62877; P63208; P68036; Q13309; Q13616; Q15843; Q9Y4X5;
13-298
ZN;SY8;
Assess
Cryo-EM structure of CDK2-CyclinA in complex with p27 from the SCFSKP2 E3 ligase Complex Heteromer
P20248; P24941; P46527;
14-297
Assess
Cdk2/cyclin A/p27-KID-deltaC Heteromer
P20248; P24941; P46527;
17-298
SO4;
Assess
Cryo-EM structure of SKP1-SKP2-CKS1-CDK2-CyclinA-p27KIP1 Complex Heteromer
P20248; P24941; P46527; P61024; P63208; Q13309;
16-296
Assess
Crystal structure of human Cdk2-Spy1-P27 ternary complex Heteromer
P24941; P46527; Q5MJ70;
19-292
Assess
Structure of CDK2/cyclin A M246Q, S247EN Heteromer
P20248; P24941;
28-295
Assess
CAND1-CUL1-RBX1-SKP1-SKP2-CKS1-CDK2 Heteromer
P24941; P61024; P62877; P63208; Q13309; Q13616; Q86VP6;
161-277
ZN;
Assess
Partially dissociated CAND1-CUL1-RBX1-SKP1-SKP2-CKS1-CDK2 Heteromer
P24941; P61024; P62877; P63208; Q13309; Q13616; Q86VP6;
165-244
Assess
CDK2 in complex with FragLite37monomer1-298
HJK;
Assess
CDK2 in complex with FragLite36monomer1-298
HGH;DMS;
Assess
CDK2 in complex with FragLite6monomer1-298
DMS;HGQ;
Assess
CDK2 in complex with FragLite34monomer1-298
DMS;HHB;
Assess
CDK2 in complex with FragLite33monomer1-298
DMS;HH5;
Assess
CDK2 in complex with FragLite38monomer1-298
HHW;EDO;
Assess
CDK2 in complex with FragLite2monomer1-298
PYZ;
Assess
CDK2 in complex with FragLite35monomer1-298
DMS;HGK;
Assess
CDK2 in complex with FragLite13monomer1-298
HHN;
Assess
CDK2 in complex with FragLite14monomer1-298
HGW;
Assess
CDK2 in complex with FragLite2monomer1-298
HEW;
Assess
CDK2 in complex with FragLite32monomer1-298
26D;
Assess
Crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitormonomer1-298
CK2;
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomer1-298
SCF;
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-Amino-6-(3'-methyl-2'-oxo)butoxypuri…monomer1-298
MBP;
Assess
CCT068127 in complex with CDK2monomer1-298
8QT;
Assess
CDK2 in complex with CGP74514Amonomer1-298
FC8;
Assess
Cyclin-free CDK2 in complex with Cpd17monomer1-298
WQ6;
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomer1-298
5SC;
Assess
CDK2 in complex 9K-DOSmonomer1-298
JLC;
Assess
CDK2 in complex with inhibitor RC-3-89monomer1-298
EDO;X64;
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomer1-298
6SC;
Assess
Crystal structure of the cdk2 in complex with oxindole inhibitormonomer1-298
60K;GOL;
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomer1-298
SCE;
Assess
Crystal structure of CDK2 in complex with TW8672monomer1-298
EDO;7TW;
Assess
CDK2 in complex with AZD5438monomer1-298
FB8;EDO;
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomer1-298
SC8;
Assess
Crystal structure of the cdk2 in complex with aminopyrazole inhibitormonomer1-298
4CK;
Assess
Crystal structure of the cdk2 in complex with aminopyrazole inhibitormonomer1-298
10K;
Assess
Crystal structure of human CDK2 (unphosphorylated) in complex with PKF049-365monomer1-298
89E;
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomer1-298
SC9;
Assess
Crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitormonomer1-298
20K;ACT;
Assess
Crystal structure of CDK2 liganded with compound EF4195monomer1-298
EDO;8KQ;
Assess
Crystal structure of the cdk2 in complex with aminopyrazole inhibitormonomer1-298
03K;
Assess
Crystal Structure of CDK2 in complex with compound 22monomer1-298
6QB;
Assess
CDK2 in complex with inhibitor KVR-2-80monomer1-298
EDO;18Z;
Assess
Crystal structure of the cdk2 in complex with oxindole inhibitormonomer1-298
LS5;NA;
Assess
CDK2 in complex with a disubstituted 4, 6-bis anilino pyrimidine CDK4 inhibitormonomer1-298
FAP;FCP;
Assess
Crystal Structure of the Cdk2 in Complex with Aminopyrazole Inhibitormonomer1-298
09K;
Assess
CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-b]PYRIDAZINEmonomer1-298
I1P;
Assess
Crystal structure of the cdk2 in complex with aminopyrazole inhibitormonomer1-298
11K;ACT;
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomer1-298
SCZ;
Assess
CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL]SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZIN…monomer1-298
GOL;7YG;
Assess
CDK2 with compound 14 inhibitor with carboxylatemonomer1-298
YOS;
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomer1-298
SCJ;
Assess
Cdk2(F80C) with Covalent Adduct TK22 at F80Cmonomer1-298
OY2;
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomer1-298
SCW;
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomer1-298
3SC;
Assess
Crystal structure of a CDK inhibitor bound to CDK2monomer1-298
6AE;
Assess
Cdk2(F80C) with Covalent Adduct TK37 at F80Cmonomer1-298
OWN;
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomer1-298
LZD;
Assess
CDK2 in complex with Dinaciclibmonomer1-298
EDO;1QK;
Assess
Crystal structure of the cdk2 in complex with oxindole inhibitormonomer1-298
61K;GOL;
Assess
CDK2 in complex with inhibitor KVR-1-160monomer1-298
EDO;X85;
Assess
CDK2 ternary complex with JWS648 and ANSmonomer1-298
2AN;JWS;
Assess
Crystal Structure of the CDK2 in complex with thiazolylpyrimidine inhibitormonomer1-298
18K;ACT;
Assess
CDK2 in complex with inhibitor KVR-1-164monomer1-298
EDO;X87;
Assess
Crystal structure of CDK2 processed with the CrystalDirect automated mounting and cryo-cooling tech…monomer1-298
Assess
CDK2 in complex with inhibitor L2monomer1-298
EDO;X11;PO4;
Assess
Cdk2(F80C)monomer1-298
Assess
Crystal structure of CDK2 in complex with 6-methoxy-7H-purine processed with the CrystalDirect auto…monomer1-298
SZL;
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomer1-298
SCQ;
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomer1-298
SCX;
Assess
Crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitormonomer1-298
16K;
Assess
CDK2 in complex with FragLite16monomer1-298
HH8;
Assess
CDK2 in complex with inhibitor KVR-1-190monomer1-298
EDO;X63;
Assess
CDK2 in complex with inhibitor RC-2-34monomer1-298
04Z;
Assess
CDK2 in complex with inhibitor KVR-1-140monomer1-298
EDO;XA0;
Assess
CDK2 in complex with inhibitor RC-2-39monomer1-298
56Z;
Assess
CDK2 in complex with inhibitor JWS-6-76monomer1-298
EDO;X67;
Assess
CDK2 in complex with inhibitor RC-2-33monomer1-298
20Z;
Assess
CDK2 in complex with inhibitor RC-2-49monomer1-298
25Z;
Assess
CDK2 in complex with inhibitor NSK-MC2-55monomer1-298
EDO;X14;
Assess
Crystal structure of the cdk2 in complex with oxindole inhibitormonomer1-298
42K;GOL;
Assess
Crystal structure of CDK2 IN complex with Inhibitor CVT-313monomer1-298
AJR;
Assess
CDK2 in complex with inhibitor RC-3-89monomer1-298
EDO;X64;
Assess
CDK2 in complex with inhibitor KVR-1-156monomer1-298
EDO;24Z;
Assess
CDK2 in complex with inhibitor KVR-1-75monomer1-298
EDO;X96;
Assess
CDK2 in complex with inhibitor RC-2-22monomer1-298
O1Z;
Assess
CDK2 in complex with inhibitor L1monomer1-298
EDO;X07;
Assess
CDK2 in complex with inhibitor KVR-1-84monomer1-298
EDO;X65;
Assess
CDK2 in complex with inhibitor KVR-1-158monomer1-298
EDO;X84;
Assess
CDK2 in complex with inhibitor KVR-1-142monomer1-298
EDO;X6A;
Assess
CDK2 in complex with inhibitor RC-2-21monomer1-298
Z68;
Assess
CDK2 in complex with inhibitor KVR-1-162monomer1-298
EDO;X86;
Assess
CDK2 in complex with inhibitor KVR-1-154monomer1-298
EDO;22Z;
Assess
CDK2 in complex with inhibitor SU9516monomer1-298
EDO;PO4;SU9;
Assess
CDK2 in complex with inhibitor KVR-2-92monomer1-298
EDO;Z14;
Assess
CDK2 in complex with inhibitor RC-2-32monomer1-298
03Z;
Assess
CDK2 in complex with inhibitor KVR-1-126monomer1-298
EDO;X72;
Assess
CDK2 in complex with inhibitor RC-2-88monomer1-298
EDO;26Z;
Assess
HUMAN CYCLIN-DEPENDENT KINASE 2monomer1-298
Assess
Crystal structure of cdk2 with an aminoimidazo pyridine inhibitormonomer1-298
628;
Assess
CDK2 in complex with inhibitor RC-1-137monomer1-298
EDO;X35;
Assess
CDK2 in complex with inhibitor RC-2-71monomer1-298
EDO;08Z;
Assess
CDK2 in complex with inhibitor KVR-1-134monomer1-298
EDO;X76;
Assess
CDK2 in complex with inhibitor KVR-1-127monomer1-298
EDO;X73;
Assess
CDK2 in complex with inhibitor L4-14monomer1-298
Z60;
Assess
CDK2 in complex with two molecules of 8-anilino-1-naphthalene sulfonatemonomer1-298
EDO;2AN;
Assess
CDK2 in complex with a disubstituted 2, 4-bis anilino pyrimidine CDK4 inhibitormonomer1-298
BYP;BWP;GOL;
Assess
Crystal Structure of the CDK2 in complex with thiazolylpyrimidine inhibitormonomer1-298
19K;
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomer1-298
2SC;
Assess
Human CDK2 in complex with isopentenyladeninemonomer1-298
ZIP;
Assess
Crystal structure of the cdk2 in complex with oxindole inhibitormonomer1-298
62K;GOL;
Assess
Novel CDK-5 inhibitors - crystal structure of inhibitor EFP with CDK-2monomer1-298
EFP;
Assess
CDK2 in complex with inhibitor L3-3monomer1-298
PO4;Z19;
Assess
CDK2 in complex with inhibitor JWS648monomer1-298
JWS;PO4;
Assess
4-Arylazo-3,5-diamino-1H-pyrazole CDK Inhibitors: SAR Study, Crystal Structure in Complex with CDK2…monomer1-298
F18;
Assess
Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitormonomer1-298
DT1;
Assess
Novel CDK-5 inhibitors - crystal structure of inhibitor EFQ with CDK-2monomer1-298
EFQ;
Assess
CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(1,1-DIMETHYLETHYL)…monomer1-298
56H;
Assess
CDK2 in complex with inhibitor NSK-MC1-6monomer1-298
Z46;
Assess
CDK2 in complex with inhibitor RC-2-132monomer1-298
X44;
Assess
Structure of CDK2 in complex with a benzimidazopyrimidinemonomer1-298
ACT;D6I;
Assess
Modulating the interaction between CDK2 and Cyclin A with a Quinoline-based inhibitormonomer1-298
2KD;
Assess
CDK2 in complex with inhibitor RC-2-13monomer1-298
EDO;X3A;
Assess
Human cyclin dependent kinase 2 (CKD2)complexed with DIN-232305monomer1-298
D05;
Assess
CDK2 in complex with inhibitor KVR-1-74monomer1-298
EDO;X9I;
Assess
CDK2 in complex with inhibitor RC-2-74monomer1-298
09Z;
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomer1-298
LZE;
Assess
CDK2 in complex with inhibitor RC-3-96monomer1-298
EDO;99Z;
Assess
CDK2 in complex with inhibitor KVR-1-91monomer1-298
EDO;19Z;
Assess
STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873monomer1-298
U73;
Assess
CDK2 in complex with inhibitor RC-1-148monomer1-298
X36;
Assess
Cyclin Dependent Kinase 2 (CDK2) with diaminopyrimidine inhibitormonomer1-298
LIA;
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027monomer1-298
NW1;
Assess
CDK2 in complex with inhibitor RC-1-136monomer1-298
Z63;
Assess
CDK2 in complex with inhibitor L3monomer1-298
X03;
Assess
CDK2 in complex with inhibitor KVR-1-102monomer1-298
EDO;X75;
Assess
Human cyclin dependent kinase 2 (cdk2) complexed with indenopyraxole DIN-101312monomer1-298
D31;
Assess
Discovery and Characterisation of 2-Anilino-4-(thiazol-5-yl) pyrimidine Transcriptional CDK Inhibit…monomer1-298
Y8L;
Assess
CDK2 in complex with inhibitor KVR-1-150monomer1-298
EDO;X62;
Assess
CDK2 in complex with inhibitor L4-12monomer1-298
06Z;
Assess
CDK2 in complex with inhibitor L4monomer1-298
EDO;X02;
Assess
CDK2 in complex with inhibitor L2-2monomer1-298
EDO;X0A;PO4;
Assess
Human cyclin dependent kinase 2 (CDK2) complexed with DPH-042562monomer1-298
D42;
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomer1-298
LZB;
Assess
HUMAN CYCLIN-DEPENDENT KINASE 2monomer1-298
MG;ATP;
Assess
CDK2 in complex with inhibitor L3-4monomer1-298
Z30;
Assess
CDK2 in complex with inhibitor RC-2-12monomer1-298
X46;
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomer1-298
LZC;
Assess
Crystal structure of the cdk2 in complex with oxindole inhibitormonomer1-298
45K;GOL;
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomer1-298
LZA;
Assess
CDK2 in complex with inhibitor JWS-6-260monomer1-298
EDO;X01;
Assess
CDK2 in complex with 3 molecules of 8-anilino-1-naphthalene sulfonatemonomer1-298
EDO;2AN;
Assess
CDK2 in complex with inhibitor L2-5monomer1-298
EDO;X06;PO4;
Assess
Crystal structure of a benzthiophene inhibitor bound to human Cyclin-dependent Kinase-2 (CDK-2)monomer1-298
B98;
Assess
CDK2 in complex with inhibitor KVR-2-88monomer1-298
EDO;Z04;
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519)…monomer1-298
GOL;LZ2;
Assess
CDK-2 with indazole inhibitor 17 bound at its active sitemonomer1-298
EZR;
Assess
CDK2 in complex with inhibitor RC-2-23monomer1-298
02Z;
Assess
Crystal structure of CDK2 in complex with 2,4,6-trioxo-1-phenyl- hexahydropyrimidine-5-carboxamide …monomer1-298
RJI;
Assess
Human cyclin dependent protein kinase 2 in complex with the inhibitor 2-Amino-6-[(R)-pyrrolidino-5'…monomer1-298
UN4;
Assess
Structure of CDK2 in complex with an imidazolyl pyrimidine, compound 5bmonomer1-298
FRT;
Assess
HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINEmonomer1-298
BRY;
Assess
CDK2 in complex with inhibitor RC-1-135monomer1-298
Z62;
Assess
CDK2 in complex with inhibitor RC-2-40monomer1-298
27Z;
Assess
Discovery and Characterisation of 2-Anilino-4-(thiazol-5-yl) pyrimidine Transcriptional CDK Inhibit…monomer1-298
CDK;
Assess
CDK2 in complex with inhibitor KVR-1-67monomer1-298
EDO;X88;
Assess
CDK2 in complex with inhibitor RC-2-143monomer1-298
Z71;
Assess
CDK2 in complex with an imidazole piperazinemonomer1-298
IM9;
Assess
Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitormonomer1-298
DT2;
Assess
CDK2 in complex with inhibitor YL1-038-31monomer1-298
0BX;PO4;
Assess
CDK2 in complex with inhibitor KVR-1-78monomer1-298
EDO;X4B;
Assess
CDK2 in complex with inhibitor NSK-MC1-12monomer1-298
EDO;X19;
Assess
CDK2 in complex with inhibitor RC-2-38monomer1-298
EDO;X40;
Assess
Crystal Structure of CDK2 in complex with pan-CDK Inhibitormonomer1-298
3I6;
Assess
CDK2 in complex with inhibitor RC-2-35monomer1-298
X43;
Assess
APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2monomer1-298
Assess
CDK2 in complex with inhibitor RC-2-135monomer1-298
X6B;
Assess
Human CDK2 in complex with olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kina…monomer1-298
CK9;
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058monomer1-298
CMG;
Assess
CDK2 in complex with inhibitor RC-3-86monomer1-298
21Z;
Assess
CDK2 in complex with inhibitor KVR-1-9monomer1-298
EDO;Z02;
Assess
CDK2 in complex with inhibitor KVR-1-124monomer1-298
EDO;X69;
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(2,5-Dichloro-thiophen-3-yl)-pyrimid…monomer1-298
CK1;
Assess
The structure of cyclin-dependent kinase 2 (CDK2) in complex with 4-[(6-amino-4-pyrimidinyl)amino]b…monomer1-298
U55;
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-Amino-4-methyl-thiazol-5-yl)-pyr…monomer1-298
CK7;
Assess
Structure of CDK2 in complex with a Pyrazolo[4,3-d]pyrimidine Bioisostere of Roscovitine.monomer1-298
404;
Assess
STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032monomer1-298
U32;
Assess
CDK-2 with indazole inhibitor 9 bound at its active sitemonomer1-298
EZV;
Assess
CDK2 in complex with SUNITINIBmonomer1-298
B49;EDO;
Assess
Crystal structure of human CDK2 complexed with a pyrazolo[1,5-a]pyrimidine inhibitormonomer1-298
CT7;
Assess
CDK2 in complex with inhibitor RC-2-72monomer1-298
07Z;
Assess
Crystal structure of CDK2 liganded with compound TW8972monomer1-298
8IL;
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomer1-298
GOL;LZ1;
Assess
CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]M…monomer1-298
LS5;
Assess
Crystal structure of CDK2 in complex with pyrazolopyrimidine inhibitormonomer1-298
ACT;PDY;
Assess
HUMAN CYCLIN-DEPENDENT KINASE 2monomer1-298
MG;ATP;
Assess
CDK2 complex with a 4-alkynyl oxindole inhibitormonomer1-298
FMD;
Assess
CDK2 in complex with inhibitor RC-2-36monomer1-298
EDO;X42;
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITORmonomer1-298
1PU;
Assess
CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[…monomer1-298
LS2;
Assess
CDK2 in complex with inhibitor RC-2-73monomer1-298
EDO;12Z;
Assess
Apo CDK2 crystallized from Jeffaminemonomer1-298
EDO;
Assess
Human cyclin dependent kinase 2 (CDK2) complexed with DIN-234325monomer1-298
D23;
Assess
CDK2 in complex with inhibitor RC-1-132monomer1-298
Z31;
Assess
CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AM…monomer1-298
LS4;
Assess
Crystal structure of CDK2 with inhibitormonomer1-298
PM1;
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomer1-298
LZ5;
Assess
Crystal structure of cyclin-dependent kinase 2 (cdk2-wt) complex with (2s)-n-(5-(((5-tert-butyl-1,3…monomer1-298
1YG;
Assess
CDK2 in complex with inhibitor RC-1-138monomer1-298
50Z;
Assess
CDK2 in complex with NSC 134199monomer1-298
0S0;EDO;
Assess
CDK2 in complex with inhibitor JWS-6-52monomer1-298
X66;
Assess
Human Cyclin Dependent Kinase 2 (CDK2) bound to azabenzimidazole derivativemonomer1-298
1N3;
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINEmonomer1-298
STU;
Assess
Human cyclin dependent kinase 2 complexed with the CDK4 inhibitormonomer1-298
1CD;
Assess
CDK2 in complex with Cpd14 (5-fluoro-4-(4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl)-…monomer1-298
N14;
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomer1-298
LZ3;
Assess
CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMIN…monomer1-298
LS3;
Assess
CDK2 in complex with staurosporinemonomer1-298
STU; 16×EDO;
Assess
Crystal structure of CDK2 with SAR60, an aminoindazole type inhibitormonomer1-298
A28;
Assess
Crystal structure of (R,S)-S-{4-[(5-Bromo-4-{[(2R,3R)-2-hydroxy-1-methylpropyl]oxy}- pyrimidin-2-yl…monomer1-298
6AF;
Assess
Crystal structure of BAY 1000394 (Roniciclib) bound to CDK2monomer1-298
R0N;
Assess
Structure of CDK2 in complex with an imidazolyl pyrimidine, compound 5cmonomer1-298
FRV;
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL Bmonomer1-298
PVB;EDO;
Assess
CDK2 ternary complex with SU9516 and ANSmonomer1-298
EDO;SU9;2AN;
Assess
CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H-PURIN-2- YLAMINE AND MONOMERIC CDK2monomer1-298
N69;
Assess
HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160monomer1-298
MG;ATP;
Assess
Human cyclin dependent protein kinase 2 in complex with the inhibitor 2-Amino-6-[cyclohex-3-enyl]me…monomer1-298
207;
Assess
CDK2 in complex with inhibitor YL5-083monomer1-298
0BY;PO4;
Assess
CDK2 in complex with inhibitor RC-2-142monomer1-298
Z67;
Assess
HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINEmonomer1-298
HMD;EDO;
Assess
Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitormonomer1-298
CT8;
Assess
Crystal structure of human CDK2 complexed with a pyrazolo[1,5-a]pyrimidine inhibitormonomer1-298
CT9;
Assess
Fragment-Based Discovery of the Pyrazol-4-yl urea (AT9283), a Multi- targeted Kinase Inhibitor with…monomer1-298
L0F;
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomer1-298
LZ9;
Assess
CDK2 in complex with the imidazole pyrimidine amide, compound (S)-8bmonomer1-298
ACT;I19;
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomer1-298
LZ8;
Assess
Structure of CDK2 with a 3-hydroxychromonesmonomer1-298
371;
Assess
THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITORmonomer1-298
106;
Assess
Crystal structure of human CDK2 complexed with a thiazolidinone inhibitormonomer1-298
C53;CL;
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITORmonomer1-298
2PU;
Assess
screening for fragment binding by X-ray crystallographymonomer1-298
CIG;
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomer1-298
LZ7;
Assess
Crystal structure of human CDK2 in complex with the inhibitor olomoucine.monomer1-298
OLO;
Assess
CDK2 complexed with N-methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonam…monomer1-298
LS1;
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomer1-298
GOL;LZ4;
Assess
THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-6,7-DIMETHOX…monomer1-298
DTQ;
Assess
Structure of CDK2 complexed with PNU-181227monomer1-298
N5B;
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomer1-298
LZM;
Assess
Crystal structure of CDK2 with SAR57, an aminoindazole type inhibitormonomer1-298
A27;
Assess
Crystal structure of a 3-aminoindazole compound with CDK2monomer1-298
740;
Assess
Crystal structure of CDK2 with a 2-aminopyrimidine compoundmonomer1-298
PMU;
Assess
Crystal structure of CDK2 IN complex with Inhibitor NU-6140monomer1-298
AQG;
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(2,4-Dimethyl-thiazol-5-yl)-pyrim…monomer1-298
CK8;
Assess
Crystal structure of human CDK2 complexed with a thiazolidinone inhibitormonomer1-298
C96;
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(2,4-Dimethyl-thiazol-5-yl)-pyrimidi…monomer1-298
CK2;
Assess
Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitormonomer1-298
DT4;
Assess
Imidazopyridines: a potent and selective class of Cyclin-dependent Kinase inhibitors identified thr…monomer1-298
HDU;
Assess
CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITORmonomer1-298
3FP;
Assess
Crystal structure of CDK2 with SAR37, an aminoindazole type inhibitormonomer1-298
A07;
Assess
Human cyclin-dependent kinase 2 in complex with roscovitinemonomer1-298
RRC;
Assess
CDK2 in complex with staurosporine and 2 molecules of 8-anilino-1-naphthalene sulfonic acidmonomer1-298
STU;2AN;EDO;
Assess
The structure of cyclin dependent kinase 2 (CKD2) with a trisubstituted naphthostyril inhibitormonomer1-298
5BN;
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-Methyl-2-methylamino-thiazol-5…monomer1-298
CK6;
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2,4-Dimethyl-thiazol-5-yl)-pyrimid…monomer1-298
CK4;
Assess
Crystal Structure of CDK2 in complex with Macrocyclic Aminopyrimidinemonomer1-298
PY8;
Assess
Crystal Structure of Human Cyclin-Dependent Kinase 2 Complexed with a Nucleoside Inhibitormonomer1-298
SU9;
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(2,4-Dimethyl-thiazol-5-yl)-pyrim…monomer1-298
CK5;
Assess
HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-…monomer1-298
RYU;
Assess
CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717monomer1-298
I17;
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITORmonomer1-298
1PU;
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(2,4-Dimethyl-thiazol-5-yl)pyrimi…monomer1-298
CK3;
Assess
CDK2 in complex with FragLite1monomer2-298
BYZ;
Assess
Discovery of (4-Pyrazolyl)-2-Aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependen…monomer2-298
XKU;
Assess
Ternary complex of CDK2 with small molecule ligands TW8672 and Roscovitinemonomer2-298
EDO;RRC;7TW;
Assess
CDK2 liganded with ATP and Mg2+monomer2-298
EDO;ATP;MG;
Assess
Crystal structure of CDK2 liganded with compound EF3019monomer2-298
EDO;8FI;
Assess
CDK2 in complex with NSC 35676monomer2-298
12×EDO;TIY;
Assess
Crystal structure of CDK2 in complex with 7-hydroxy-4-(morpholinomethyl)chromen-2-one processed wit…monomer2-298
WY3;
Assess
Crystal structure of CDK2 in complex with 6-chloro-7H-purine processed with the CrystalDirect autom…monomer2-298
ES4;
Assess
CDK2 in complex with NSC 111848monomer2-298
3TI;EDO;
Assess
DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGNmonomer1-297
MTW;
Assess
CDK2 in complex with FragLite7monomer1-296
DMS;HHQ;
Assess
CDK2 in complex with FragLite31monomer1-296
HHT;
Assess
Crystal structure of the cdk2 in complex with aminopyrazole inhibitormonomer1-296
1CK;NA;
Assess
Crystal structure of apo CDK2monomer1-296
Assess
Crystal structure of CDK2 liganded with compound WN333monomer3-298
EDO;80E;
Assess
The structure of cyclin-dependent kinase 2 (CDK2) in complex with Compound 1monomer1-296
65L;
Assess
Crystal structure of the cdk2 in complex with oxindole inhibitormonomer1-296
46K;
Assess
Crystal structure of CDK2 liganded with compound GPHR787monomer3-298
7TH;
Assess
Crystal structure of the cdk2 in complex with oxindole inhibitormonomer1-296
48K;
Assess
Imidazopyridines: a potent and selective class of Cyclin-dependent Kinase inhibitors identified thr…monomer3-298
HDT;
Assess
Crystal structure of CDK2 in complex with N-(9H-purin-6-yl)thiophene- 2-carboxamide processed with …monomer3-298
ZXC;
Assess
Ternary complex of CDK2 with small molecule ligands TW8672 and Dinaciclibmonomer3-298
EDO;1QK;7TW;
Assess
Cyclin-free CDK2 in complex with Cpd21monomer1-296
GOL;WQK;
Assess
CDK2 IN COMPLEX WITH COMPOUND 4monomer1-296
3I3;
Assess
Crystal structure of CDK2 liganded with compound WN378monomer3-298
8KF;
Assess
Cdk2(F80C, C177A) with covalent adduct at C80monomer1-296
AEQ;
Assess
Crystal structure of CDK2 in complex with inhibitor BS-194monomer3-298
NS9;
Assess
CDK2 in complex with a disubstituted 2, 4-bis anilino pyrimidine CDK4 inhibitormonomer1-296
GOL;FAL;FBL;
Assess
CDK2 in complex with a disubstituted 4, 6-bis anilino pyrimidine CDK4 inhibitormonomer1-296
MFP;MFQ;
Assess
Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitormonomer1-296
DT5;
Assess
Imidazopyridines: a potent and selective class of Cyclin-dependent Kinase inhibitors identified thr…monomer1-296
HDY;
Assess
Crystal structure of CDK2 liganded with compound EF2252monomer3-298
EDO;88O;
Assess
Crystal structure of CDK2 in complex with inhibitor ICEC0943monomer3-298
I73;
Assess
Crystal structure of CDK2 in complex with inhibitor ICEC0942monomer3-298
ACT;I74;
Assess
Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitormonomer1-296
CT6;
Assess
Crystal structure of CDK2 liganded with compound WN316monomer3-298
EDO;8IQ;
Assess
Human CDK2 with type II inhibitormonomer1-296
LQ5;
Assess
CDK2 in complex with Luciferinmonomer3-298
ESJ;
Assess
Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitormonomer1-296
4SP;
Assess
Crystal structure of Cdk2 in complex with Cyclin A inhibitor 6-[(E)-2-(4-chlorophenyl)ethenyl]-2-{[…monomer1-296
OW6;
Assess
Crystal structure of human CDK2 complexed with a thiazolidinone inhibitormonomer1-296
C62;
Assess
Human cyclin-dependent kinase 2 in complex with inhibitor HB-29260monomer2-297
W5W;GOL;
Assess
Cdk2(WT) covalent adduct with D28 at C177monomer2-296
9YZ;
Assess
CDK2 with EGFR inhibitor compound 8monomer1-295
ACT;3QS;
Assess
Cdk2(WT) with covalent adduct at C177monomer2-296
AAK;
Assess
CDK2 liganded with para chloro ANSmonomer1-295
N5R;PO4;EDO;
Assess
Cdk2(F80C, C177A) covalent adduct with C37 at F80Cmonomer4-298
9Z2;
Assess
Structure of cyclin-dependent kinase 2 with small-molecule ligand 4- fluorobenzoic acid (AT222) in …monomer1-295
1Y6;ACE;
Assess
Structure of cyclin-dependent kinase 2 with small-molecule ligand 3-(4,7-dichloro-1H-indol-3-yl)pro…monomer1-294
MFZ;
Assess
The structure of cyclin dependent kinase 2 (CKD2) with a pyrazolobenzodiazepine inhibitormonomer1-294
2BZ;
Assess
Aerosol-soaked human cdk2 crystals with Staurosporinemonomer1-294
STU;EDO;
Assess
Cdk2(F80C, C177A) with covalent ligand at F80Cmonomer2-294
9ZB;
Assess
CDK2 in complex with a Luciferin derivatemonomer3-295
WG8;
Assess
Crystal structure of CDK2 in complex with 2-imidazol-1-yl-1H- benzimidazole processed with the Crys…monomer2-294
5JE;
Assess
Structure of CDK2 in complex with FP24322, a Helicon Polypeptidemonomer9-294
EDO;WHL;
Assess

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
3eid.1.Amonomer0.851-297
PO5;100.00
Assess